Takashi et al[9] demonstrated that osimertinib regressed bone tumors in mice with EGFR-mutant lung adenocarcinoma and bone metastases, resulting in improved survival and bone remodeling in the mice. The gene discussed is EGFR; the disease is lung adenocarcinoma.